Galectin Therapeutics (GALT) Change in Cash (2010 - 2026)

Galectin Therapeutics' Change in Cash history runs 17 years deep, the most recent figure standing at -$3.6 million for Q1 2026.

• On a quarterly basis, Change in Cash rose 53.06% year-over-year to -$3.6 million in Q1 2026; TTM through Mar 2026 was $6.7 million, a 141.43% increase from a year earlier, with the FY2025 full-year figure at $2.6 million, up 124.67% from the prior year.
• Change in Cash eased to -$3.6 million in Q1 2026 per GALT's latest filing, from $6.2 million in the prior quarter.
• Across five years, Change in Cash topped out at $6.3 million in Q2 2025 and bottomed at -$11.9 million in Q4 2024.
• The 5-year median for Change in Cash is -$793000.0 (2023), against an average of -$1.5 million.
• Biggest YoY gain for Change in Cash was 1123.35% in 2024; the steepest drop was 325.37% in 2024.
• Year by year, Change in Cash stood at $2.8 million in 2022, then surged by 91.89% to $5.3 million in 2023, then tumbled by 325.37% to -$11.9 million in 2024, then jumped by 151.88% to $6.2 million in 2025, then sank by 158.26% to -$3.6 million in 2026.
• Per Business Quant, the three latest GALT Change in Cash figures stand at -$3.6 million (Q1 2026), $6.2 million (Q4 2025), and -$2.2 million (Q3 2025).